Mesoblast Limited Share Price & Technical Analysis
MESO · $15.20 (+1.47%)
Healthcare / Biotechnology
$15.20
+1.47%
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-4% return in May, 3% avg return in past 3 year May month.
-15% return in 2026, 71% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | -8% | 4% | -1% | -4% | – | – | – | – | – | – | – | -15% |
| 25 | -3% | -12% | -21% | -6% | -11% | 4% | 28% | -9% | 23% | 5% | 5% | 5% | 7% |
| 24 | -18% | 11% | 150% | 6% | 4% | -11% | 0% | 0% | 21% | 2% | 39% | 69% | 275% |
| 23 | 12% | -8% | 2% | -12% | 15% | 15% | -1% | -58% | -17% | -4% | 8% | -19% | -68% |
| 22 | -18% | -6% | 11% | -14% | -5% | -36% | 40% | -8% | -12% | 5% | 23% | -23% | -44% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.86B
P/E ratio
—
52W high
$21.50
52W low
$9.88
Volume
1,15,563
Beta
0.79
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Mesoblast Limited share price today?
- Mesoblast Limited (MESO) last traded around $15.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MESO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MESO. Download the app for real-time alerts.
- How can I analyze Mesoblast Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.